CAR-T cell therapy, antibody-drug conjugates (ADCs) and immunotherapy are among the most talked-about advances in cancer treatment — and among the most misunderstood when it comes to cost and access in India. This guide explains, plainly, what these treatments are, what they realistically cost in India in 2026, and who actually benefits from them.
What these treatments actually are
They are not one thing, and they are not for every cancer:
- Immunotherapy (checkpoint inhibitors) — releases the brakes on your own immune system. Used in several cancers, guided by markers such as PD-L1 or MSI.
- CAR-T cell therapy — a patient’s own T-cells are re-engineered to attack the cancer. Used mainly in certain relapsed blood cancers.
- Antibody-drug conjugates (ADCs) — an antibody that homes in on a cancer marker, carrying a chemotherapy payload directly to the cell. A fast-growing class in breast, bladder and other cancers.
Who actually benefits
This is the part that matters most, because these therapies are powerful but specific:
- CAR-T is used in selected relapsed or refractory leukemia, lymphoma and multiple myeloma — often alongside or instead of a bone marrow transplant.
- Immunotherapy helps a subset of patients whose tumours carry the right markers — which is why precision-medicine testing is done first.
- ADCs are used where the tumour expresses the specific target the antibody recognises.
In each case, a test result — not the diagnosis alone — decides whether the treatment can help. Given to the wrong patient, these drugs neither work nor justify their cost.
The real question with these therapies is never just ‘can we afford it?’ It is ‘will it work for this specific tumour?’ The testing that answers the second question is what makes the first one worth asking.
What they cost in India — and how to think about it
Costs vary widely and change over time, so treat any figure as a broad guide rather than a quote. In general, checkpoint immunotherapy is given over many cycles and adds up over months; ADCs are similarly ongoing; and CAR-T is a very high one-time cost, though Indian-made CAR-T has begun to bring that down compared with imported therapy. Because the numbers are large and moving, the sensible approach is to get a clear, written estimate for your specific plan rather than relying on headline figures.
Our financial guidance can help you understand costs and the insurance or assistance options that may apply, and patients travelling for treatment can plan through our international patients page.
The questions to ask before committing
Before starting any of these treatments, you should have clear answers to: what test confirms this will help me; what is the realistic goal; how many cycles or what one-time cost; what are the side effects; and is there an equally effective, less expensive option? If the plan was made elsewhere, a second opinion is especially worthwhile here, because these are exactly the decisions where the right testing and the right patient selection change everything.
Frequently asked questions
Is immunotherapy suitable for every cancer?
No. It helps a subset of patients whose tumours carry the right markers. Testing decides suitability.
Is CAR-T available in India?
Yes — Indian CAR-T therapy is now available for selected blood cancers, and has started to reduce the cost compared with imported options.
Are these always better than chemotherapy?
Not always. For many patients, chemotherapy or targeted therapy remains the most effective and appropriate treatment. Newer is not automatically better for your specific cancer.
How do I know if it is worth the cost?
The honest answer comes from testing and a frank discussion of the goal. A specialist review can tell you whether the treatment fits your tumour before you spend anything.
Related reading: Immunotherapy · Targeted Therapy · Precision Medicine · Leukemia Specialist · Lymphoma Specialist · Multiple Myeloma Specialist · Bone Marrow Transplant · Financial Guidance · Cancer Second Opinion
Reviewed by Dr. Harish Kancharla
DM (Medical Oncology), AIIMS, New Delhi · MD (Internal Medicine), PGIMER, Chandigarh
Senior Consultant – Medical Oncology & Hemato-Oncology, Yashoda Hospitals, Somajiguda, Hyderabad
Telangana State Medical Council Registration No. 77186
Last reviewed: July 2026
This article is general information, not personal medical advice. Cancer decisions depend on your individual diagnosis, stage, test results and overall health. Please see our Medical Disclaimer.